BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22383691)

  • 21. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
    Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
    J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
    Deeks ED; Raymond E
    BioDrugs; 2011 Oct; 25(5):307-16. PubMed ID: 21942915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
    Ito T; Igarashi H; Jensen RT; Takayanagi R
    Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic NETs: where do we stand now?
    Faivre S; Castellano D; Strosberg J; González E; Salazar R
    Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
    Procopio G; Pusceddu S; Buzzoni R
    Tumori; 2012; 98(3):394. PubMed ID: 22825518
    [No Abstract]   [Full Text] [Related]  

  • 29. [Erlotinib, sunitinib, and everolimus].
    Takahashi M
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():409-13. PubMed ID: 25857058
    [No Abstract]   [Full Text] [Related]  

  • 30. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Phan AT
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):3-5. PubMed ID: 25768101
    [No Abstract]   [Full Text] [Related]  

  • 31. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in pancreatic neuroendocrine tumor treatment.
    Castellano D; Grande E; Barriuso J
    N Engl J Med; 2011 May; 364(19):1872-3; author reply 1873-4. PubMed ID: 21561356
    [No Abstract]   [Full Text] [Related]  

  • 33. New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
    Dong M; Phan AT; Yao JC
    Clin Cancer Res; 2012 Apr; 18(7):1830-6. PubMed ID: 22338018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
    Bisht S; Feldmann G; Brossart P
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
    Unno M
    Nihon Shokakibyo Gakkai Zasshi; 2010 Mar; 107(3):392-5. PubMed ID: 20203442
    [No Abstract]   [Full Text] [Related]  

  • 36. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus for the treatment of pancreatic neuroendocrine tumors.
    Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
    Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New therapeutic options for metastatic malignant insulinomas.
    de Herder WW; van Schaik E; Kwekkeboom D; Feelders RA
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):277-84. PubMed ID: 21649688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
    Maxwell JE; Sherman SK; Howe JR
    Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.